Global CINV Existing and Pipeline Drugs Market Insights, Forecast to 2025

1 Study Coverage

• 1.1 CINV Existing and Pipeline Drugs Product Introduction
• 1.2 Market Segments
• 1.3 Key CINV Existing and Pipeline Drugs Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type
  • 1.4.2 Aloxi (palonosetron)
  • 1.4.3 Zofran Generic (ondansetron)
  • 1.4.4 Kytril Generic (granisetron)
  • 1.4.5 Emend (aprepitant)
  • 1.4.6 Akynzeo (netupitant-palonosetron)
  • 1.4.7 SUSTOL (extended release granisetron injection)
  • 1.4.8 Rolapitant
• 1.5 Market by Application
  • 1.5.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application
  • 1.5.2 Hospitals
  • 1.5.3 Specialty Clinics
  • 1.5.4 Diagnostic Centers Therapeutics
  • 1.5.5 Hospital Pharmacies
  • 1.5.6 Drugstores
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global CINV Existing and Pipeline Drugs Market Size, Estimates and Forecasts
  • 2.1.1 Global CINV Existing and Pipeline Drugs Revenue 2015-2026
  • 2.1.2 Global CINV Existing and Pipeline Drugs Sales 2015-2026
• 2.2 Global CINV Existing and Pipeline Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global CINV Existing and Pipeline Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global CINV Existing and Pipeline Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global CINV Existing and Pipeline Drugs Competitor Landscape by Players

• 3.1 CINV Existing and Pipeline Drugs Sales by Manufacturers
  • 3.1.1 CINV Existing and Pipeline Drugs Sales by Manufacturers (2015-2020)
  • 3.1.2 CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2015-2020)
• 3.2 CINV Existing and Pipeline Drugs Revenue by Manufacturers
  • 3.2.1 CINV Existing and Pipeline Drugs Revenue by Manufacturers (2015-2020)
  • 3.2.2 CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global CINV Existing and Pipeline Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by CINV Existing and Pipeline Drugs Revenue in 2019
  • 3.2.5 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 CINV Existing and Pipeline Drugs Price by Manufacturers
• 3.4 CINV Existing and Pipeline Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers CINV Existing and Pipeline Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global CINV Existing and Pipeline Drugs Market Size by Type (2015-2020)
  • 4.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2015-2020)
  • 4.1.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2015-2020)
  • 4.1.3 CINV Existing and Pipeline Drugs Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global CINV Existing and Pipeline Drugs Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2021-2026)
  • 4.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Type (2021-2026)
  • 4.2.3 CINV Existing and Pipeline Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global CINV Existing and Pipeline Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global CINV Existing and Pipeline Drugs Market Size by Application (2015-2020)
  • 5.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2015-2020)
  • 5.1.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2015-2020)
  • 5.1.3 CINV Existing and Pipeline Drugs Price by Application (2015-2020)
• 5.2 CINV Existing and Pipeline Drugs Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2021-2026)
  • 5.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global CINV Existing and Pipeline Drugs Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America CINV Existing and Pipeline Drugs by Country
  • 6.1.1 North America CINV Existing and Pipeline Drugs Sales by Country
  • 6.1.2 North America CINV Existing and Pipeline Drugs Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Type
• 6.3 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Application

7 Europe

• 7.1 Europe CINV Existing and Pipeline Drugs by Country
  • 7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Country
  • 7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Type
• 7.3 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific CINV Existing and Pipeline Drugs by Region
  • 8.1.1 Asia Pacific CINV Existing and Pipeline Drugs Sales by Region
  • 8.1.2 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Type
• 8.3 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America CINV Existing and Pipeline Drugs by Country
  • 9.1.1 Latin America CINV Existing and Pipeline Drugs Sales by Country
  • 9.1.2 Latin America CINV Existing and Pipeline Drugs Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America CINV Existing and Pipeline Drugs Market Facts & Figures by Type
• 9.3 Central & South America CINV Existing and Pipeline Drugs Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa CINV Existing and Pipeline Drugs by Country
  • 10.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country
  • 10.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Type
• 10.3 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Application

11 Company Profiles

• 11.1 GlaxoSmithKline
  • 11.1.1 GlaxoSmithKline Corporation Information
  • 11.1.2 GlaxoSmithKline Description and Business Overview
  • 11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
  • 11.1.5 GlaxoSmithKline Related Developments
• 11.2 Helsinn
  • 11.2.1 Helsinn Corporation Information
  • 11.2.2 Helsinn Description and Business Overview
  • 11.2.3 Helsinn Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Helsinn CINV Existing and Pipeline Drugs Products Offered
  • 11.2.5 Helsinn Related Developments
• 11.3 Heron Therapeutics
  • 11.3.1 Heron Therapeutics Corporation Information
  • 11.3.2 Heron Therapeutics Description and Business Overview
  • 11.3.3 Heron Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products Offered
  • 11.3.5 Heron Therapeutics Related Developments
• 11.4 Merck
  • 11.4.1 Merck Corporation Information
  • 11.4.2 Merck Description and Business Overview
  • 11.4.3 Merck Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Merck CINV Existing and Pipeline Drugs Products Offered
  • 11.4.5 Merck Related Developments
• 11.5 Tesaro
  • 11.5.1 Tesaro Corporation Information
  • 11.5.2 Tesaro Description and Business Overview
  • 11.5.3 Tesaro Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Tesaro CINV Existing and Pipeline Drugs Products Offered
  • 11.5.5 Tesaro Related Developments
• 11.1 GlaxoSmithKline
  • 11.1.1 GlaxoSmithKline Corporation Information
  • 11.1.2 GlaxoSmithKline Description and Business Overview
  • 11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
  • 11.1.5 GlaxoSmithKline Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 CINV Existing and Pipeline Drugs Market Estimates and Projections by Region
  • 12.1.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Regions 2021-2026
  • 12.1.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Regions 2021-2026
• 12.2 North America CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
  • 12.2.1 North America: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
  • 12.2.2 North America: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
  • 12.2.3 North America: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
• 12.3 Europe CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
  • 12.3.1 Europe: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
  • 12.3.2 Europe: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
  • 12.3.3 Europe: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: CINV Existing and Pipeline Drugs Market Size Forecast by Region (2021-2026)
• 12.5 Latin America CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
  • 12.5.2 Latin America: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key CINV Existing and Pipeline Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 CINV Existing and Pipeline Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details